Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review

Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review

More than 40 tyrosine kinase inhibitors (TKIs) have received hematological or oncological indications over the past 20 years, following the approval of imatinib, and many others are currently being tested in clinical and preclinical level. Beyond their common toxicities, no certain agent from this l...

Full description

Bibliographic Details
Main Authors: Dimitrios C. Ziogas, Dimitrios Mandellos, Charalampos Theocharopoulos, Panagiotis-Petros Lialios, Spyros Bouros, Paolo A. Ascierto, Helen Gogas
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
TKIs (tyrosine kinase inhibitors)
metastatic cancer
myasthenia (myasthenia gravis—MG)
targeted therapies
case report
review—systematic
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.727010/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.727010/full

Similar Items